We are live on ! Find out more
IBT

International Biotechnology Trust Portfolio holdings

AUM $297M
1-Year Est. Return 17.25%
This Fund
S&P 500
This Quarter Est. Return
+15.42%
1 Year Est. Return
+17.25%
3 Year Est. Return
+11.14%
5 Year Est. Return
+79.35%
10 Year Est. Return
–
AUM
$324M
AUM Growth
+$11.9M
Cap. Flow
-$17.7M
Cap. Flow %
-5.47%
Top 10 Hldgs %
51.2%
Holding
69
New
3
Increased
9
Reduced
7
Closed
6

Top Buys

Rank Stock Value
1
MRTX
Mirati Therapeutics, Inc. Common Stock
MRTX
+$6.99M
2
PTCT icon
PTC Therapeutics
PTCT
+$5.11M
3
ILMN icon
Illumina
ILMN
+$4.58M
4
TVTX icon
Travere Therapeutics
TVTX
+$4.09M
5
AZN icon
AstraZeneca
AZN
+$4.08M

Top Sells

Rank Stock Value
1
GILD icon
Gilead Sciences
GILD
+$12M
2
HZNP
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
+$11.6M
3
BIIB icon
Biogen
BIIB
+$6.81M
4
LKFT
Lakefront Biotherapeutics American Depositary Shares
LKFT
+$5.25M
5
INCY icon
Incyte
INCY
+$4.59M

Sector Composition

Rank Sector Weight
1 Healthcare 99.98%
2 Miscellaneous 0.02%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
UTHR icon
26
United Therapeutics
UTHR
$22.6B
$4.17M 1.29%
15,000
– –
ASND icon
27
Ascendis Pharma A/S
ASND
$16.4B
$3.59M 1.11%
29,400
– –
KRYS icon
28
Krystal Biotech
KRYS
$10.6B
$3.56M 1.1%
45,000
– –
ONC
29
BeOne Medicines Ltd
ONC
$42.1B
$3.45M 1.07%
15,700
– –
JAZZ icon
30
Jazz Pharmaceuticals
JAZZ
$16.3B
$2.74M 0.85%
17,200
– –
AUPH icon
31
Aurinia Pharmaceuticals
AUPH
$2.19B
$2.48M 0.77%
573,530
– –
ZLAB icon
32
Zai Lab
ZLAB
$3.01B
$2.42M 0.75%
78,958
– –
NVCR icon
33
NovoCure
NVCR
$2.09B
$2.34M 0.72%
32,000
– –
RVNC
34
DELISTED
Revance Therapeutics, Inc.
RVNC
$2.21M 0.68%
120,000
– –
GH icon
35
Guardant Health
GH
$22.6B
$2.02M 0.63%
74,500
– –
IDYA icon
36
IDEAYA Biosciences
IDYA
$4.03B
$1.98M 0.61%
109,000
– –
LEGN icon
37
Legend Biotech
LEGN
$3.99B
$1.89M 0.59%
38,000
– –
APLS
38
DELISTED
Apellis Pharmaceuticals
APLS
$1.64M 0.51%
+31,700
New +$1.68M
CRBU icon
39
Caribou Biosciences
CRBU
$178M
$1.62M 0.5%
257,892
– –
ACAD icon
40
Acadia Pharmaceuticals
ACAD
$5.12B
$1.59M 0.49%
+100,000
New +$1.56M
FULC icon
41
Fulcrum Therapeutics
FULC
$294M
$1.41M 0.44%
193,741
– –
CRSP icon
42
CRISPR Therapeutics
CRSP
$5.74B
$1.39M 0.43%
34,200
– –
ACET icon
43
Adicet Bio
ACET
$84.3M
$1.38M 0.43%
9,669
– –
NVAX icon
44
Novavax
NVAX
$1.49B
$1.36M 0.42%
132,500
– –
MIRM icon
45
Mirum Pharmaceuticals
MIRM
$6.08B
$1.31M 0.41%
67,500
+58,281
+632% +$1.15M
NBP
46
NovaBridge Biosciences American Depositary Shares
NBP
$219M
$1.29M 0.4%
310,499
-196,740
-39% -$745K
RCKT icon
47
Rocket Pharmaceuticals
RCKT
$397M
$1.23M 0.38%
63,000
– –
CNCE
48
DELISTED
Concert Pharmaceuticals, Inc.
CNCE
$1.17M 0.36%
200,800
– –
DNLI icon
49
Denali Therapeutics
DNLI
$3.94B
$1.06M 0.33%
38,000
– –
XENE icon
50
Xenon Pharmaceuticals
XENE
$6B
$1M 0.31%
25,500
– –
1
2
3

Similar funds

DCMIC
Decheng Capital Management III (Cayman) Grand Cayman, Cayman Islands $300M AUM 15.74% 1-Year Est. Return
DT
Daniels + Tansey Wilmington, Delaware $289M AUM 18.06% 1-Year Est. Return
3LCM
3D/L Capital Management Hartford, Connecticut $308M AUM 13.67% 1-Year Est. Return
TFA
Triad Financial Advisors Greensboro, North Carolina $284M AUM 14.95% 1-Year Est. Return
SFG
Steward Financial Group Colleyville, Texas $315M AUM 13.78% 1-Year Est. Return
AEPLI
AH Equity Partners LSV I Menlo Park, California $315M AUM 9.31% 1-Year Est. Return
CC
Chanos & Company New York $318M AUM 4.62% 1-Year Est. Return
BC
Brahman Capital New York $275M AUM 18.08% 1-Year Est. Return

International Biotechnology Trust's Q4 2022 Portfolio in Review

As of Q4 2022, International Biotechnology Trust held 69 positions worth $324M, up 3.8% from $312M the previous quarter. Its ten largest holdings account for 51% of the portfolio.

International Biotechnology Trust withdrew a net $17.7M in Q4 2022, closing 6 positions and reducing 7 holdings. Its most notable exit was Lakefront Biotherapeutics American Depositary Shares, an estimated $5.25M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, down from 100% a quarter earlier, followed by Miscellaneous.

Against the trend, International Biotechnology Trust opened a new position in AstraZeneca worth $4.41M.

  • International Biotechnology Trust's largest Q4 2022 buy was AstraZeneca: 32,500 shares worth $4.41M.
  • International Biotechnology Trust added most to Mirati Therapeutics, Inc. Common Stock in Q4 2022, an estimated $6.99M increase.
  • International Biotechnology Trust's biggest Q4 2022 reduction was Gilead Sciences, cutting an estimated $12M.
  • International Biotechnology Trust fully exited Lakefront Biotherapeutics American Depositary Shares in Q4 2022, selling an estimated $5.25M.
  • International Biotechnology Trust's ten largest holdings make up 51% of its $324M portfolio in Q4 2022.
  • International Biotechnology Trust opened 3 new positions and closed 6 in Q4 2022.
  • International Biotechnology Trust's portfolio value rose 3.8% quarter-over-quarter to $324M.

Based on International Biotechnology Trust's 13F filing for Q4 2022, filed 1 Feb 2023.